Variations in the number of regulatory T cells (CD4+CD25+) in patients with breast cancer during Herceptin therapy

• DOI: 10.1007/s10517-006-0171-7
• Publication Date: 2006-06-14T12:14:29Z
• Authors: E. G. Slavina; A. I. Chertkova; T. N. Zabotina; I. P. Gan’shina; M. R. Lichinitser
• Keywords: Adult; T-Lymphocytes; Interleukin-2 Receptor alpha Subunit; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Middle Aged; Trastuzumab; Antibodies, Monoclonal, Humanized; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; CD4 Antigens; Humans; Female

We studied the effect of Herceptin therapy on the population composition of lymphocytes and percentage of CD4+CD25+ cells (regulatory T cells) in breast cancer patients. Herceptin treatment decreased the number of "professional" T suppressors (CD4+CD25+ cells and regulatory T cells) in the peripheral blood.